• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Venezuela receives first shipment of Cuban coronavirus vaccine

firstwordpharmaJune 25, 2021

Tag: Venezuela , Cuban coronavirus , Vaccine

Venezuela’s vice president Delcy Rodriguez said the country received its first shipment of doses of Cuba's Abdala COVID-19 vaccine on Thursday, as reported in This is Money.

Venezuela receives first shipment of Cuban coronavirus vaccine

Authorities did not specify how many doses had arrived, but said that Venezuela had signed a contract to purchase 12 million doses of the vaccine. 

Earlier this week, Cuba said that the three-shot Abdala vaccine had proved 92.28% effective in last-stage clinical trials.

Since February, Venezuela has received some 3.5 million doses of Russian and Chinese vaccines for its population of approximately 28 million. 


Previous:OncoSec Appoints Brian Leuthner as Interim CEO

Next:Hospital Factors Tied to Greater COVID-19 Mortality in Blacks

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Venezuela receives first shipment of Cuban coronavirus vaccine | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Pet Vaccine Series

Pet Vaccine Series
Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral

Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral
Poliomyelitis Vaccine Type I Type III in Dragee Candy (Human Diploid Cell), Live

Poliomyelitis Vaccine Type I Type III in Dragee Candy (Human Diploid Cell), Live
2024-2025 quadrivalent flu vaccine

2024-2025 quadrivalent flu vaccine
Hualan BIO Influenza Vaccine (Split virion)

Hualan BIO Influenza Vaccine (Split virion)
2024-2025 trivalent flu vaccine WHO-PQ

2024-2025 trivalent flu vaccine WHO-PQ
Influenza Vaccine, Live, Nasal, Freeze-dried

Influenza Vaccine, Live, Nasal, Freeze-dried
2024-2025 quadrivalent/trivalent flu vaccine

2024-2025 quadrivalent/trivalent flu vaccine
High-standard and high quality Influenza Vaccine (Split virion), inactivated

High-standard and high quality Influenza Vaccine (Split virion), inactivated
2019-nCoV Vaccine(Vero Cells),Inactivated

2019-nCoV Vaccine(Vero Cells),Inactivated

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service